Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients.
about
Microparticles as Biomarkers of Blood Coagulation in CancerClinical significance of procoagulant microparticlesBiomolecular markers of cancer-associated thromboembolismOn the origin of microparticles: From "platelet dust" to mediators of intercellular communicationVenous thromboembolism in malignant gliomasRecent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives.Circulating microparticles: square the circle.Microparticles in hemostasis and thrombosis.Techniques for the analysis of extracellular vesicles using flow cytometryHigh plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.Cancer and coagulation.The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis.Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway.Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome.Microparticles, malignancy and thrombosis.The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.Coagulation and metastasis: what does the experimental literature tell us?Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill.Microparticle analysis in disorders of hemostasis and thrombosis.Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?Techniques to improve detection and analysis of extracellular vesicles using flow cytometry.Internalization of Tissue Factor-Rich Microvesicles by Platelets Occurs Independently of GPIIb-IIIa, and Involves CD36 Receptor, Serotonin Transporter and Cytoskeletal Assembly.
P2860
Q26783691-36F7D583-A6A2-40C6-8844-A44D4054EC35Q26830846-E014793F-F1A4-48E4-B04F-13A56095155BQ26865716-2793CEF5-902C-460F-86BE-C7CA7BBC8F53Q27023547-45E4C111-A1CC-4290-A1EF-F1B626949035Q30436810-D6CA38F8-BAE9-4A86-B40C-465A554A517EQ33581791-A458A216-C4D5-49F4-BF7A-E2B944087916Q34680832-C616F1A7-C00D-4C71-AF60-335CB74F93D1Q35131040-3B223560-1A7A-4AF4-81D5-E3F8480711EFQ35460716-F988AFD6-205B-467C-898B-734D7EE39838Q36152165-201CD0F1-C770-4818-A074-C23B257DBCF1Q36391554-AC428DC5-DF2C-4829-B363-0A180DC0F6BDQ37129768-BBC80F16-7B5D-4A52-B8DE-761F10ED6D96Q37169096-F4A953C1-3F40-46FB-8A90-238660A13A1AQ37331535-87ED9A9B-3F23-4F6F-93C7-56B9607D775DQ37349421-FD698465-6060-41CF-88CB-16080454C0E8Q37474995-55E90F77-883A-47EA-B09D-373847BDC928Q37837956-A4C6FF16-9173-416F-ACE0-E8953B92B51DQ37866790-A35CC3F0-B490-4C5E-BB7B-F27CDC1DBDC2Q38108356-EAC6E2DB-20B5-4E5D-8A76-C8B6A296F5DBQ38117740-0FF5D29D-BF1A-440B-8EAA-E824C4167A1EQ38364069-9E84C9CB-E178-400E-81BD-99F3218D8470Q38783439-0CD173E5-4736-45E6-A72E-33CC91B1D1C1Q39182335-28DD4FC1-2898-483E-AE7D-D9FB13F9A5D8Q41969213-C3651B3E-B6E1-4911-93A7-6ADC7E9362ECQ54256171-F0710D94-FD65-469A-B7F7-262A08FC1466
P2860
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Tissue factor activity is incr ...... e sample from cancer patients.
@en
type
label
Tissue factor activity is incr ...... e sample from cancer patients.
@en
prefLabel
Tissue factor activity is incr ...... e sample from cancer patients.
@en
P2093
P2860
P1433
P1476
Tissue factor activity is incr ...... e sample from cancer patients.
@en
P2093
Jorge Nieva
Nigel Mackman
Rachel E Tilley
Rajesh Belani
Todd Holscher
P2860
P304
P356
10.1016/J.THROMRES.2007.12.023
P577
2008-02-11T00:00:00Z